stockportfolio.pro
ADMA Biologics, Inc. P/E Ratio 2011–2025
ADMA Biologics, Inc. (ADMA) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +2.6%/yr over 14 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 30.40 | +43.6% |
| FY 2024 | 21.17 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
Source: ADMA Biologics, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for ADMA Biologics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeADMA Biologics, Inc. — frequently asked questions
What is ADMA Biologics, Inc.'s price-to-earnings ratio?
ADMA Biologics, Inc. (ADMA) reported price-to-earnings ratio of 30.40 for fiscal year 2025, per its SEC filings.
How has ADMA Biologics, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2011 and 2025, ADMA's price-to-earnings ratio grew at roughly 2.6% per year (compound annual rate), from 21.17 to 30.40.
Where does this data come from?
Figures are computed from ADMA Biologics, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.